Contaminant Removal Using Vibrating Surfaces: Nanoscale Insights and a Universal Scaling Law.

The development of active self-cleaning surfaces, i.e., surfaces that remove nanoscale contaminants using external forces such as electric or magnetic fields, is critical to many engineering applications.

The Impact of COVID on Early Intervention Parenting Support for Mothers in Recovery from Substance Use Disorder.

COVID-19 adversely impacted parents with substance use disorders (SUDs) as evidenced by increased overdoses. This study used a qualitative approach to examine COVID's impact on experiences and perceptions of a parenting program designed for mothers in recovery from SUDs, "Mothering from the Inside Out" (MIO), implemented through Early Intervention (EI) home-visiting services. Four EI programs participated in training and implementation of MIO.

Spatially distinct cellular and molecular landscapes define prognosis in triple negative breast cancer.

Background-: Triple-negative breast cancer is a prevalent breast cancer subtype with the lowest 5-year survival. Several factors contribute to its treatment response, but the inherent molecular and cellular tumor heterogeneity are increasingly acknowledged as crucial determinants.

Methods-: Spatial transcriptomic profiling was performed on FFPE tissues from a retrospective, treatment-naive group of women with differential prognoses (17 with >15 years survival- good prognosis (GPx) and 15 with <3 years survival-poor prognosis (PPx)) using GeoMX Digital Spatial Profiler.

Cooperative nutrient scavenging is an evolutionary advantage in cancer.

The survival of malignant cells within tumours is often seen as depending on ruthless competition for nutrients and other resources. Although competition is certainly critical for tumour evolution and cancer progression, cooperative interactions within tumours are also important, albeit poorly understood. Cooperative populations at all levels of biological organization risk extinction if their population size falls below a critical tipping point.

Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T cell lymphoma.

Selective targeting of the functionally exhausted malignant T cells in cutaneous T-cell lymphoma (CTCL) and distinct cells within the tumor microenvironment (TME) via PD1/PD-L1 blockade (durvalumab) may restore an anti-tumor immune response. The oral immunomodulator lenalidomide, which has activity in CTCL, may enhance durvalumab immune checkpoint blockade. Our phase 1/2 clinical trial of durvalumab and lenalidomide in patients with refractory/advanced CTCL (NCT03011814) sought to assess safety and tolerability and identify the maximum tolerated dose/recommended phase 2 dose (RP2D) of lenalidomide plus fixed-dose durvalumab.